Table 2.

Variables considered in multivariate analysis

Patient related:

Age at transplant: ≤60 years* vs. >60 years

Karnofsky performance at transplant: <90%* vs. ≥90% vs. missing

Gender: male* vs female

Disease related:

Histological type of NHL

Immunophenotype: B-cell* vs. T cell vs. missing

Time from diagnosis to transplant: <12 months* vs. ≥ 24 months vs. 12–24 months

Number of lines of therapy: ≤2* vs. 3–4 vs. ≥5

Disease status at transplant: CR2* vs. PIF sens vs. PIF res vs. Rel sens vs. Rel res vs.

Rel untreated/unknown/missing

Chemosensitive disease at transplant: Sensitive* vs. resistant vs. not evaluable/untreated/missing

Marrow involvement at diagnosis: yes* vs no

Duration of CR1: continuous

Transplant related:

Conditioning regimen: TBI* vs. non-TBI

Conditioning regimen: ATG given vs no ATG given*

Donor type/HLA match: Unrelated well matched* vs. Unrelated partially matched vs. Unrelated mismatched vs mismatched family member donor

Source of stem cells: Bone marrow* vs. peripheral blood

GVHD prophylaxis: FK506+MTX±Others* vs. MTX+CsA+others vs. CsA+others vs. T cell depletion+others vs. FK506 ± Other

Donor-recipient CMV status: +/+* vs. +/− vs. −/+ vs. −/−

Donor-recipient gender match: M-M* vs. M-F vs. F-M vs. F-F

Year of transplant: 1997–2000* vs. 2001–2002 vs. 2003–2004

Abbreviations: DLCL = diffuse large cell lymphoma; PTCL = peripheral T cell lymphoma; PIF = primary induction failure; CR = complete remission; REL = relapse; res = resistant; sens = sensitive; TBI = total body radiation; GVHD = graft vs. host disease; CsA = cyclosporine; FK506 = tacrolimus; MTX = methotrexate; CMV = cytomegalovirus; M= male; F = female.